Annexon, Inc. financial data

Symbol
ANNX on Nasdaq
Industry
Pharmaceutical Preparations
Location
1400 Sierra Point Parkway, Bldg C, Suite 200, Brisbane, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 3, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.61K % +42.1%
Debt-to-equity 15.3 % -37.1%
Return On Equity -44.3 % +33.4%
Return On Assets -38.4 % +28.2%

Shares

Label TTM Value / Value Unit Change %
Common Stock, Shares, Outstanding 109M shares +39.6%
Entity Public Float 477M USD +295%
Common Stock, Value, Issued 109K USD +39.7%
Weighted Average Number of Shares Outstanding, Basic 137M shares +81.6%
Weighted Average Number of Shares Outstanding, Diluted 137M shares +81.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 119M USD +5%
General and Administrative Expense 34.6M USD +15.5%
Operating Income (Loss) -154M USD -7.2%
Net Income (Loss) Attributable to Parent -138M USD -2.95%
Earnings Per Share, Basic -1.01 USD/shares +42.9%
Earnings Per Share, Diluted -1.01 USD/shares +42.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 49.5M USD -78%
Cash, Cash Equivalents, and Short-term Investments 312M USD +20.1%
Other Assets, Current 23K USD -86.1%
Assets, Current 316M USD +19.9%
Property, Plant and Equipment, Net 12.6M USD -14.5%
Operating Lease, Right-of-Use Asset 16.7M USD -7.24%
Other Assets, Noncurrent 3.24M USD
Assets 350M USD +17.6%
Accounts Payable, Current 10.4M USD +90%
Accrued Liabilities, Current 10.7M USD +19%
Liabilities, Current 30.5M USD +70.2%
Operating Lease, Liability, Noncurrent 26.5M USD -9.37%
Liabilities 57M USD +20.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 10K USD
Retained Earnings (Accumulated Deficit) -711M USD -24.1%
Stockholders' Equity Attributable to Parent 293M USD +17%
Liabilities and Equity 350M USD +17.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -28.3M USD +14.3%
Net Cash Provided by (Used in) Financing Activities 32.4M USD +84.4%
Net Cash Provided by (Used in) Investing Activities -77.3M USD -496%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 109M shares +39.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 50.5M USD -77.7%
Deferred Tax Assets, Valuation Allowance 181M USD +38.2%
Deferred Tax Assets, Gross 186M USD +36.2%
Operating Lease, Liability 29M USD -7.6%
Depreciation 2.2M USD +4.76%
Payments to Acquire Property, Plant, and Equipment 137K USD -97.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -138M USD -3.15%
Lessee, Operating Lease, Liability, to be Paid 38.3M USD -11.3%
Property, Plant and Equipment, Gross 19.8M USD +0.08%
Operating Lease, Liability, Current 2.52M USD +16.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.24M USD +3.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 5.07M USD +3.52%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9.36M USD -21.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.43M USD +3.49%
Deferred Tax Assets, Operating Loss Carryforwards 94.2M USD +32.7%
Unrecognized Tax Benefits 8.42M USD +112%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.62M USD +3.5%
Additional Paid in Capital 1B USD +22%
Depreciation, Depletion and Amortization 538K USD +0.37%
Deferred Tax Assets, Net of Valuation Allowance 4.98M USD -10.6%
Share-based Payment Arrangement, Expense 19.4M USD +6.88%